Chest

1. AL-NAAMANI N, Thenappan T
   Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy.
   Chest. 2024;165:766-768.
   

   >> Share

   
   

   
   Circ Heart Fail

2. TURGEON RD, Fernando S, Bains M, Code J, et al
   Qualitative Analysis of Patient Decisional Needs for Medications to Treat Heart Failure.
   Circ Heart Fail. 2024;17:e011445.
   

   >> Share

   
   
3. THOMPSON JS
   GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions.
   Circ Heart Fail. 2024 Apr 6:e011653. doi: 10.1161/CIRCHEARTFAILURE.124.011653.
   

   >> Share

   
   

   
   Circulation

4. SANDHU AT, Calma J, Skye M, Kalwani NM, et al
   Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic.
   Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624.
   

   >> Share

   
   
5. HERNANDEZ AF, Udell JA, Jones WS, Anker SD, et al
   Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial.
   Circulation. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217.
   

   >> Share

   
   
6. HOEDEMAKERS S, Pugliese NR, Stassen J, Vanoppen A, et al
   mPAP/CO Slope and Oxygen Uptake Add Prognostic Value in Aortic Stenosis.
   Circulation. 2024 Feb 27. doi: 10.1161/CIRCULATIONAHA.123.067130.
   

   >> Share

   
   

   
   Eur Heart J

7. CREA F
   The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing.
   Eur Heart J. 2024;45:1183-1187.
   

   >> Share

   
   
8. RUZIEH M
   Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
   Eur Heart J. 2024;45:1284.
   

   >> Share

   
   

   
   Eur J Heart Fail

9. FERREIRA JP, Packer M, Sattar N, Butler J, et al
   Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme.
   Eur J Heart Fail. 2024 Apr 8. doi: 10.1002/ejhf.3227.
   

   >> Share

   
   
10. 
    HFA Winter Research Meeting on Translational Heart Failure 2024 In collaboration with the ESC Working Group on Myocardial Function, 11 - 14 May 2024, Lisbon & Online.
    Eur J Heart Fail. 2024;26 Suppl 1:3-16.
    

    >> Share

    
    
11. UREY MA, Hibbert B, Jorde U, Eckman P, et al
    Left atrial to coronary sinus shunting for treatment of heart failure with mildly reduced or preserved ejection fraction: The ALT FLOW Early Feasibility Study 1-year results.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3241.
    

    >> Share

    
    
12. BEAVERS CJ, Bhatt DL, Gotter G
    Reply to 'The pharmacist ally in heart failure: Useful when involved'.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3242.
    

    >> Share

    
    
13. PASCUAL-FIGAL DA, Hernandez-Vicente A, Pastor-Perez F, Martinez-Selles M, et al
    N-terminal pro-B-type natriuretic peptide post-discharge monitoring in the management of patients with heart failure and preserved ejection fraction - a randomized trial: The NICE study.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3222.
    

    >> Share

    
    
14. ZILE MR, Lindenfeld J, Weaver FA, Zannad F, et al
    Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3232.
    

    >> Share

    
    
15. LI J, Chen Y, Wang Y, Liu X, et al
    Impact of guideline-directed medical therapy on systolic blood pressure and cardiovascular outcomes in patients with heart failure and low blood pressure: A systematic review and meta-analysis.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3208.
    

    >> Share

    
    
16. HEIDECKER B, Pagnesi M, Luscher TF
    Heart failure and respiratory tract infection: Cause and consequence of acute decompensation?
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3209.
    

    >> Share

    
    
17. SETTERGREN C, Benson L, Shahim A, Dahlstrom U, et al
    Cause-specific death in heart failure across the ejection fraction spectrum: A comprehensive assessment of over 100 000 patients in the Swedish Heart Failure Registry.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3230.
    

    >> Share

    
    
18. MULLENS W, Damman K, Dhont S, Banerjee D, et al
    Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC.
    Eur J Heart Fail. 2024 Apr 12. doi: 10.1002/ejhf.3244.
    

    >> Share

    
    
19. BHATT AS, Vaduganathan M, Jena BP, Suminska S, et al
    Comparative effectiveness of sacubitril/valsartan versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with de novo heart failure with mildly reduced and preserved ejection fraction.
    Eur J Heart Fail. 2024 Apr 7. doi: 10.1002/ejhf.3233.
    

    >> Share

    
    

    
    Int J Cardiol

20. CAI Q, Li Q, Zhong S, Chen M, et al
    Ultrasound-targeted microbubble destruction rapidly improves left ventricular function in rats with ischemic cardiac dysfunction.
    Int J Cardiol. 2024;404:131943.
    

    >> Share

    
    
21. NAKAO M, Nagai T, Anzai T
    Iron supplementation is a residual piece of management in Asian patients with heart failure?
    Int J Cardiol. 2024 Apr 4:132014. doi: 10.1016/j.ijcard.2024.132014.
    

    >> Share

    
    
22. GLINGE C, Rossetti S, Oestergaard LB, Stampe NK, et al
    Familial clustering of unexplained heart failure - A Danish nationwide cohort study.
    Int J Cardiol. 2024 Apr 5:132028. doi: 10.1016/j.ijcard.2024.132028.
    

    >> Share

    
    
23. ESPERSEN C, Campbell RT, Claggett BL, Lewis EF, et al
    Predictors of heart failure readmission and all-cause mortality in patients with acute heart failure.
    Int J Cardiol. 2024 Apr 8:132036. doi: 10.1016/j.ijcard.2024.132036.
    

    >> Share

    
    

    
    J Am Coll Cardiol

24. NEIJENHUIS RML, MacDonald ST, Zemrak F, Mertens BJA, et al
    Effect of Sodium-Glucose Cotransporter 2 Inhibitors in Adults With Congenital Heart Disease.
    J Am Coll Cardiol. 2024;83:1403-1414.
    

    >> Share

    
    
25. CHATUR S, Neuen BL, Claggett BL, Beldhuis IE, et al
    Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.
    J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06691.
    

    >> Share

    
    
26. UDELL JA, Petrie MC, Jones WS, Anker SD, et al
    Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction.
    J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06757.
    

    >> Share

    
    
27. MARTON A, Saffari SE, Rauh M, Sun RN, et al
    Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure.
    J Am Coll Cardiol. 2024;83:1386-1398.
    

    >> Share

    
    
28. BURCHILL LJ, Jain CC, Miranda WR
    Advancing New Solutions for Adult Congenital Heart Disease-Related Heart Failure.
    J Am Coll Cardiol. 2024;83:1415-1417.
    

    >> Share

    
    

    
    J Card Fail

29. SHIN S, Kowahl N, Hansen T, Ling AY, et al
    Real-world walking behaviors are associated with early-stage heart failure: a Project Baseline Health Study.
    J Card Fail. 2024 Apr 4:S1071-9164(24)00113.
    

    >> Share

    
    
30. HAYWOOD HB, Graham AJ, Chermak D, Achanta A, et al
    Estimating the Proportion of Heart Failure Admissions Potentially Eligible for Hospital at Home.
    J Card Fail. 2024 Mar 27:S1071-9164(24)00108.
    

    >> Share

    
    
31. SHOJI S, Kaltenbach LA, Granger BB, Fonarow GC, et al
    Remote Follow-up in a Heart Failure Pragmatic Trial: Insights From the CONNECT-HF.
    J Card Fail. 2024 Apr 4:S1071-9164(24)00109.
    

    >> Share

    
    
32. CARTER S, Thibodeau JT
    Patient Focus: Moving Beyond Step Count. An Explanation of Real-world walking behaviors are associated with early-stage heart failure: a Project baseline Health Study.
    J Card Fail. 2024 Apr 9:S1071-9164(24)00115.
    

    >> Share

    
    
33. LALA A, Sinha SS, Fang J
    HFSA at the 10(th) Anniversary Meeting of the Heart Failure Association of India - New Partnerships and Opportunities Overseas.
    J Card Fail. 2024;30:523-524.
    

    >> Share

    
    

    
    J Cardiol

34. VLACHAKIS PK, Tsiachris D, Doundoulakis I, Tsioufis P, et al
    Therapeutic inertia in rhythm control strategies in hospitalized patients with fibrillation: Insights from Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study.
    J Cardiol. 2024;83:313-317.
    

    >> Share

    
    
35. MAKHOUL GW, Mustafa A, Wei C, Ling J, et al
    Heart failure - An unexplored risk factor for infective endocarditis after pacemaker implantation.
    J Cardiol. 2024 Apr 5:S0914-5087(24)00061-3. doi: 10.1016/j.jjcc.2024.
    

    >> Share

    
    

    
    Lancet

36. DONAL E, L'Official G, Istratoaie S
    Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
    Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
    

    >> Share

    
    
37. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
    Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
    Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
    

    >> Share

    
    

    
    N Engl J Med

38. BYUN JH, Nguyen S
    Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.
    N Engl J Med. 2024;390:1343-1344.
    

    >> Share

    
    
39. ROULEAU J
    Decreasing the Risk of Heart Failure in a Changing Post-Myocardial Infarction Environment.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMe2402719.
    

    >> Share

    
    
40. KOSIBOROD MN, Petrie MC, Borlaug BA, Butler J, et al
    Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
    N Engl J Med. 2024 Apr 6. doi: 10.1056/NEJMoa2313917.
    

    >> Share

    
    
41. PINTEA BENTEA G, Castro Rodriguez J
    Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure.
    N Engl J Med. 2024;390:1344.
    

    >> Share

    
    
42. SAPP JL, Sivakumaran S, Tang ASL
    Long-Term Outcomes of Resynchronization-Defibrillation for Heart Failure. Reply.
    N Engl J Med. 2024;390:1343-1345.
    

    >> Share

    
    

    
    PLoS One

43. EL-MALAHI O, Mohajeri D, Mincu R, Bauerle A, et al
    Beneficial impacts of physical activity on heart rate variability: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0299793.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share